Skip to main content

REVIEW article

Front. Bioeng. Biotechnol.
Sec. Biomaterials
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1499474
This article is part of the Research Topic Multifunctional nanomaterials: Stand in the Center of Cancer Therapy as well as Tissue Regeneration and Repair View all 3 articles

Cancer Theragnostics: Closing the Loop for Advanced Personalized Cancer Treatment through the Platform Integration of Therapeutics and Diagnostics

Provisionally accepted
Olga Sergeeva Olga Sergeeva 1Liang Luo Liang Luo 2,3Anthony Guiseppi Elie Anthony Guiseppi Elie 4,5,6*
  • 1 Genterra JSC, Moscow, Moscow Oblast, Russia
  • 2 Huazhong University of Science and Technology, Wuhan, Hubei Province, China
  • 3 National Engineering Research Center for Nanomedicine, Wuhan, China
  • 4 Texas A and M University, College Station, United States
  • 5 Houston Methodist Research Institute, Houston, Texas, United States
  • 6 ABTECH Scientific, Inc, Richmond, United States

The final, formatted version of the article will be published soon.

    Cancer continues to be one of the leading causes of death worldwide, and conventional cancer therapies such as chemotherapy, radiation therapy, and surgery have limitations. RNA therapy and cancer vaccines hold considerable promise as an alternative to conventional therapies for their ability to enable personalized therapy with improved efficacy and reduced side effects. The principal approach of cancer vaccines is to induce a specific immune response against cancer cells. However, a major challenge in cancer immunotherapy is to predict which patients will respond to treatment and to monitor the efficacy of the vaccine during treatment. Theragnostics, an Sergeeva, Luo and Guiseppi-Elie, Cancer Theragnostics 2 | P a g e integration of diagnostic and therapeutic capabilities into a single hybrid platform system, has the potential to address these challenges by enabling real-time monitoring of treatment response while allowing endogenously controlled personalized treatment adjustments. In this article, we review the current state-of-the-art in theragnostics for cancer vaccines and RNA therapy, including imaging agents, biomarkers, and other diagnostic tools relevant to cancer, and their application in cancer therapy development and personalization. We also discuss the opportunities and challenges for further development and clinical translation of theragnostics in cancer vaccines.

    Keywords: Theragnostics, cancer vaccine, RNA therapy, biomarkers, Immunotherapy, personalized medicine, feedback control

    Received: 20 Sep 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Sergeeva, Luo and Guiseppi Elie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Anthony Guiseppi Elie, Texas A and M University, College Station, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.